Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for April 2009
April 1, 2009
- Hythiam Announces Results of Two Double-Blind, Placebo-Controlled Studies on Impact of PROMETA Treatment Program for Alcohol Dependence
- Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
- Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
April 2, 2009
- Labopharm Reports Results for Phase III Study on Twice-daily Tramadol-acetaminophen Formulation
- IDEA reports results from a prospective 3 years phase III study of Diractin (ketoprofen in Transfersome gel)
- Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
April 3, 2009
- Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
- New Study Demonstrates Improvements in LDL-Cholesterol on Top of Statin Therapy with HEP-40, a Novel Natural Product
April 6, 2009
- Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
- Zosano Pharma, Inc. Presents Positive Phase 2 Results of Its Needle-Free Osteoporosis Therapy
April 7, 2009
- Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial
- Cerepro Phase III trial update
- AngioChem to Present New ANG1005 Clinical Data at AACR
- Phase I/II Trials of Anti-Androgen Drugs Show Promise for Patients with Advanced Prostate Cancer
April 8, 2009
- Study Shows Single Dose of Reclast Prevents Postmenopausal Osteoporosis for at Least 2 Years
- Kiadis Pharma Reports ATIR Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
- Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties
- The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
- bioXell S.p.A (CH) - BioXell reports top-line OAB Phase IIb results
- Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Large Breast Cancer Tumors
- ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
- Parkinson's Disease Medication Triggers Destructive Behaviors
April 9, 2009
- OTHERA Announces Positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD
- New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
- Data on AVEO Pharmaceuticals' AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting
- Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
April 10, 2009
- ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting
- Curis Announces Presentations at American Association for Cancer Research Annual Meeting 2009
- Lancet Publication of Juvista (INN: Avotermin) Trial Results for the Improvement of Skin Scarring
- Enzyme Therapy Slows Kidney Function Decline
April 13, 2009
- Crofelemer, First-in-Class Anti-Diarrheal Agent, Positive Clinical Results to be Discussed at 13th Annual US-Japan CMSP in Kolkata, India
- Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting
- Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
- Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
- New Approach to Progesterone Supplementation in ART Revealed in Recently Published White Paper
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
April 14, 2009
- Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
- Provenge Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
- Erectile Dysfunction Treatments Do Not Appear to Damage Vision Over Six Months
- Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009
- Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting
- Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control
- Evotec AG (DE) - Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
- Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
- Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II Reolysin and Radiation Combination Clinical Trial
April 15, 2009
- AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
- Pro-Pharmaceuticals' DAVANAT Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated
- Angiotech Pharmaceuticals, Inc. - New study shows that Zilver PTX effectively treats blockages in critical thigh artery
- Telik Announces Preclinical Presentations at AACR Annual Meeting
- Lorus Announces Report of Evidence of Clinical Activity in Clinical Trial of LOR-2040 Combined With Capecitabine and Oxaliplatin in the Treatment of Advanced Metastatic Solid Tumors
- Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors
- American Association for Cancer Research Hosts 100th Annual Meeting
- Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009
- Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology
- Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
April 16, 2009
- MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research
- Novagali Pharma completed a new Phase II with Cyclokat in dry eye
- Cytopia Presentation on VDA CYT997 at AACR Conference
- Alternative Therapy for Lupus Nephritis
April 17, 2009
- Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC
- Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
- Promising interim results from Hybrigenics' Inecalcitol Phase II in Combination with Taxotere(R) for Hormone-Refractory Prostate Cancer
- ERYtech Pharma Presents Very Encouraging Results of Its R&D Platform at the AACR in Denver
April 20, 2009
- Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
- Dendreon Announces Data on Provenge Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
- Lorus Therapeutics Presents New Findings for First-in-class Anticancer Drug Candidate LOR-253
- Pantec Biosolutions Reports Successful Phase I Study into the Delivery of Triptorelin Using P.L.E.A.S.E.R Technology
- Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
- Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
- Allos Therapeutics' Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines
- Array BioPharma's ARRY-614 Demonstrates Cytokine Inhibition and Anti-Tumor Activity in Preclinical Models of Hematological Cancers
- Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056
- Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
April 21, 2009
- Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594's Prodrug, RDEA806
- Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
- AngioChem Presents New Positive Clinical Data on ANG1005 for Brain Cancers at AACR
- New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR
- Array BioPharma's ARRY-543 Shows Potential Clinical Benefit in Cancer Patients
- Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
- Bioalliance Pharma Presents Results on Its New Biotherapy Plasmid AMEP for Metastatic Melanoma at the American Association for Cancer Research (AACR) 100Th Annual Meeting in Denver, April 18 to 22, 2009
- Seven Abstracts Featuring Exelixis Compounds to Be Presented at 2009 ASCO Annual Meeting
- Isotechnika announces positive 12 month data from PROMISE trial
- New study shows that re-treatment with Pegasys provides hep C patients with second chance for cure
- NSLIJ Scientists to Present EKC-Cide Study Results at the GTC-Bio Conference on Ocular Diseases and Drug Discovery
- Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva)-resistant Lung Cancer Models
- Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
- SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting
- Abstract on ˜Chemoablation of Metastatic Melanoma' Accepted for Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology
- AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer
- Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
- International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation
April 22, 2009
- Clavis Pharma ASA (NO) - Promising Elacytarabine Clinical Results Presented at AACR
- Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
- Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio
- Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting
- Geron Presentations on Imetelstat (GRN163L) at the AACR 2009 Annual Meeting
- Curis Presents CUDC-305 Preclinical Data at the AACR 100th Annual Meeting 2009
- Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
- Lorus Therapeutics Announces Presentation of New Supportive Data for LOR-2040 in Acute Myeloid Leukemia
- Tranzyme Pharma Announces Positive Phase 2 Results with TZP-101 for Improvement of Symptoms in Patients with Gastroparesis
- Celator Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
- Anergis SA Announces Successful Results of a Phase I/IIA Clinical Trial with Subcutaneous AllerT, its Novel Product for Desensitization of Patients Allergic to Birch Pollen
- GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Urological Association
- Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
- NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
- Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
- AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
April 23, 2009
- Pennsaid Phase 3 Study Results to be Published in Leading International PAIN Journal
- Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
April 24, 2009
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
- Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
- Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine
- Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C
- ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
- InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
- SCYNEXIS' SCY-635 Demonstrates Clinically Relevant Single-Agent Results in a Phase 1b Study in Adults with HCV
- Argos Therapeutics Presents Research Validating Feasibility and Safety of its Arcelis™ Personalized Immunotherapy Platform for HIV
- Medivir: New Phase IIa Data on TMC435 in Patients with Hepatitis C Presented at the Ongoing EASL - Meeting
- Opexa Publication of Tovaxin Clinical Data in Journal of Clinical Immunology
- Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
- Cannabis Compounds Reduce Multi-Drug Resistant Infections
- New Publication of Landmark Study Demonstrates Gamunex Improves Health-Related Quality of Life in Patients with CIDP
- Drug Therapy Reduces Neuroblastoma Tumor Growth in Pre-clinical Investigation
April 25, 2009
- OctoPlus N.V. (NL) - OctoPlus' licensee Biolex presents Locteron Phase IIa results at EASL conference
- GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial
- Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
April 26, 2009
- Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
- Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study
- Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
- Lancet Publishes Phase 3 Clinical Data on Basen®
April 27, 2009
- Prostate Study Shows Botox May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
- Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
- Phase II Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
- Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial
- Dynavax Presents Additional Phase 3 Data for HEPLISAV Hepatitis B Vaccine at EASL Medical Conference
- Sepracor Reports Preliminary Phase III Study Results for OMNARIS HFA Nasal Aerosol in Seasonal Allergic Rhinitis
- Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
- Curis Presents Preclinical Data for CU-903 at Keystone Symposia Event “PI3 Kinase Signaling in Disease”
- Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting
- VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study
- First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
- Dynavax Presents Additional Phase 3 Data for Heplisav Hepatitis B Vaccine at EASL Medical Conference
- New Data Presented at AUA's Annual Conference Prove GELNIQUE (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
- Theratechnologies presents additional data from studies evaluating tesamorelin at the Annual Canadian Conference on HIV/AIDS Research
- Tadalafil May Effectively Treat Symptoms of BPH-LUTS in Addition to Erectile Dysfunction
- CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
- Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
April 28, 2009
- Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
- Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
- Clinical Update - Debio 025 in Hepatitis C
- PharmAthene Presents Data for SparVax, a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
- Presented Data Confirm That Rapaflo (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
- Data Presented at AUA Demonstrate Provenge Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
- Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
- Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
- Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
- Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
- Cempra Pharmaceuticals Inc. Announces Lead Macrolide is Active in vitro Against Clinically Significant Antibiotic-Resistant Pathogenic Organisms
April 29, 2009
- Excellent Phase III results of Biofrontera's BF-200 ALA presented at dermatology congress
- Active Biotech (SE) - Active Biotech presents S100A9 as a target for quinoline compounds
- Isotechnika announces Phase 3 ESSENCE data meets primary endpoint in psoriasis
- New data presented at American Academy of Neurology congress show 80-83% of MS patients on oral FTY720 were relapse-free for one year
- MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
- Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
- Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma
- New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir
- Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show
- New Treatment Discovered for Restless Legs Syndrome Improves Sleep
- Addex Pharmaceuticals (CH) - Addex Presents Data on ADX10059 at the Annual Meeting of the American Academy of Neurology
- Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
- Advaxis' Phase 1 Clinical Cervix Cancer Study Accepted for Publication in Leading Peer-Reviewed Science Journal Vaccine
- New Analyses from 16-Year Follow-up Trial with Betaseron Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
- Long-Term Study with Copaxone Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
April 30, 2009
- Phase 3 Data on VIVUS' Qnexa to Be Presented at 17th European Congress on Obesity
- Novartis International AG (CH) - Novartis investigational adjuvanted (MF59) pre-pandemic avian influenza vaccine Aflunov shows long lasting, broadly cross-protective immune response
- UCB (BE) - UCB announces first results from Phase III brivaracetam studies in epilepsy
- Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
- LifeCycle Pharma Announces Positive Interim Results of Phase 2 Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection in De Novo Kidney Transplant Patients
- A Phase IIb Study Testing the Combination of Methotrexate and CF101 in Rheumatoid Arthritis Patients Failed to Achieve Primary Efficacy Endpoint
- Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR
- Sciele Pharma and Plethora Solutions Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation
- Provectus Abstract Titled “Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)" to be Presented at ASCO Scientific Program on June 1 in Orlando
- Dynavax Presents Data From Novel Universal Flu Vaccine Candidate
- Solifenacin Shows Superior Tolerability Compared to Oxybutynin Immediate-Release
- Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis
- Quigley Pharma Announces Drug Study That May Reverse Diabetic Peripheral Neuropathy
- First Ten-Year Follow-Up Shows That Treatment with AVONEX Leads to Long-Term Benefits in Early Multiple Sclerosis Patients
